Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

Cancer Immunology, Immunotherapy · Published 2021-06-01 · Available online 2 Jan 2021 · Journal article · DOI 10.1007/s00262-020-02793-4 · PMID: 33388994 · PMC · Cited by 18 (Crossref)

Authors (14)

Carlos Zamora, Mariona Riudavets, Georgia Anguera, Letícia Alserawan, Ivana Sullivan, Andrés Barba, Jorgina Serra, M. Angels Ortiz, Pablo Gallardo, Lidia Perea, Javier Gavira, Agustí Barnadas, Margarita Majem, Silvia Vidal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

70

Issue

6

Pages

1691-1704

Year

2021

Citation

Zamora, C., Riudavets, M., Anguera, G., et al. (2021). Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02793-4

Related articles

• Blood immune profiling predicts surgical anatomy and facial nerve outcome in Vestibular Schwannoma · Journal of Neuro-Oncology · 2026 · Cites or is cited by this article
• The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitors-related myocarditis: a retrospective cohort study · Internal and Emergency Medicine · 2024 · Cites or is cited by this article
• Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis · Cancer and Metastasis Reviews · 2025 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

18